| Literature DB >> 24994923 |
Al B Benson, Alan P Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S Cooper, Paul F Engstrom, Peter C Enzinger, Moon J Fenton, Charles S Fuchs, Jean L Grem, Steven Hunt, Ahmed Kamel, Lucille A Leong, Edward Lin, Wells Messersmith, Mary F Mulcahy, James D Murphy, Steven Nurkin, Eric Rohren, David P Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M Skibber, Constantinos T Sofocleous, Elena M Stoffel, Eden Stotsky-Himelfarb, Christopher G Willett, Kristina M Gregory, Deborah A Freedman-Cass.
Abstract
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24994923 DOI： 10.6004/jnccn.2014.0099
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908